 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | ScTIL210 / Chineo Medical Technology, Beijing Cancer Hospital
Trial completion date, Trial primary completion date: A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov) - Apr 12, 2023
P1/2, N=58, Recruiting, Sponsor: Shanghai East Hospital
Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
- | ScTIL210 / Chineo Medical Technology, Beijing Cancer Hospital
New P1 trial, Combination therapy: Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors (clinicaltrials.gov) - Feb 15, 2023
P1, N=48, Not yet recruiting, Sponsor: Peking University
- | ScTIL / Chineo Medical Technology
New P1 trial, Metastases: A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - Aug 12, 2022
P1, N=48, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- | ScTIL / Chineo Medical Technology
New P2a trial: Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies (clinicaltrials.gov) - Apr 21, 2022
P2a, N=30, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | ScTIL210 / Chineo Medical Technology, Beijing Cancer Hospital
Enrollment open: A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov) - Jul 14, 2021
P1/2, N=58, Recruiting, Sponsor: Shanghai East Hospital
Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023 Not yet recruiting --> Recruiting
- | ScTIL210 / Chineo Medical Technology, Beijing Cancer Hospital
New P1/2 trial: A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov) - Sep 30, 2020
P1/2, N=58, Not yet recruiting, Sponsor: Shanghai East Hospital
- | ScTIL210 / Chineo Medical Technology, Beijing Cancer Hospital
New P1 trial: The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma (clinicaltrials.gov) - Apr 21, 2020
P1, N=32, Not yet recruiting, Sponsor: Beijing Cancer Hospital